High-Impact Health Interventions

How a dFDA compares to history’s best health wins
Abstract
By redirecting 1% of global military spending to hyper-efficient pragmatic clinical trials, humanity can achieve 514 years of medical research in 20 years and shift the cure of every disease forward by 8.2 years, saving 416 million lives and generating $1.2 quadrillion in value.
Keywords

war-on-disease, 1-percent-treaty, medical-research, public-health, peace-dividend, decentralized-trials, dfda, dih, victory-bonds, health-economics, cost-benefit-analysis, clinical-trials, drug-development, regulatory-reform, military-spending, peace-economics, decentralized-governance, wishocracy, blockchain-governance, impact-investing

A dFDAcompetes with smallpox eradication as history’s best health intervention by ROI, cost per quality-adjusted life year, and total impact.

QALY Comparison Chart

Note: The bar represents the mid-point of the uncertainty range, and the error bars indicate the lower and upper bounds of the estimate. For “Smallpox Eradication,” the upper bound is illustrative of its high, open-ended impact.

Comparison Table

Intervention Estimated ROI (Return per $1) Cost per QALY Gained (ICER) QALYs Gained per $1M Notes & Sources
Decentralized drug assessment framework 1.19M:1 (PRIMARY: all core benefits) Dominant (cost-saving) 5,000–90,000+ Systemic, global, leverages all R&D; see Cost-Benefit Analysis
Smallpox Eradication 159:1 to 400:1 Dominant (cost-saving) 10,000+ Smallpox eradication ROI
Childhood Vaccination (US) 10:1 to 16:1 Dominant (cost-saving) 1,000–10,000 Childhood vaccination
Clean Water & Sanitation (LMICs) 4:1 to 21:1 Dominant/very cost-effective 1,000–10,000 Clean water & sanitation
Tobacco Control (taxes, bans) 20:1 to 1,057:1 Dominant/very cost-effective 1,000–10,000 Tobacco control
Hypertension Screening & Treatment Varies / Cost-Saving $500–$1,600 200–2,000 Hypertension screening
Statins for High-Risk Patients Varies / Cost-Saving £280–£8,530 50–200 Statins
Polypill for Primary Prevention (High-Risk) Varies / Cost-Saving up to £18,811 per QALY 50-200 Polypill
Generic Drug Substitution Highly Cost-Saving Dominant (cost-saving) 100–1,000 Generic drugs

Key

  • ROI: Return on investment; dollars saved or value created per $1 spent.
  • Cost per QALY Gained (ICER): Lower is better; “Dominant” means saves money and improves health. Values may be in USD ($) or GBP (£).
  • QALYs Gained per $1M: Rough estimate, varies by context and population.

Conclusion

A decentralized drug assessment framework is projected to have a higher ROI and more QALYs per dollar than almost any other single health intervention, rivaled only by foundational public health measures like smallpox eradication and mass vaccination in low-resource settings. Most other interventions, while highly cost-effective, do not approach the systemic leverage or scale of such a framework.

Reuse